Table 1.
Characteristics of patients.
| Variables | ||
|---|---|---|
| Age* | 53 ± 12.3 years | (26–71 years) |
| Gender | ||
| Male | 0 | |
| Female | 50 | |
| ECOG performance status | ||
| 0 | 24 | |
| 1 | 18 | |
| 2 | 8 | |
| Height** | 155.6 ± 3.7 cm | (150–162 cm) |
| Body weight** | 55.1 ± 11.2 kg | (42–84 kg) |
| Body mass index** | 22.8 ± 4.4 | (16.2–33.8) |
| The cycle in which patients developed grade 2 or 3 nausea despite standard antiemetic therapy | ||
| 1 | 29 | |
| 2 | 11 | |
| 3 | 6 | |
| 4 | 4 | |
| Type of cancer | ||
| Uterine cervical cancer | 23 | |
| Uterine corpus cancer | 22 | |
| Uterine carcinosarcoma | 2 | |
| Ovarian cancer | 2 | |
| Vaginal cancer | 1 | |
| Regimen of anticancer chemotherapy | ||
| AP (adriamycin 60 mg/m2, cisplatin 50 mg/m2) | 22 | |
| CPT-11/CDDP (irinotecan 60 mg/m2, cisplatin 60 mg/m2) | 8 | |
| CDDP (cisplatin 50 mg/m2) | 5 | |
| FP (5-fluorouracil 700 mg/m2 × 4 days, cisplatin 70 mg/m2)*** | 3 | |
| TP (paclitaxel 135 mg/m2, cisplatin 50 mg/m2) | 3 | |
| EP (etoposide 100 mg/m2 × 3 days, cisplatin 80 mg/m2) | 2 | |
| IP (ifosphamide 1.5 g/m2 × 4 days, cisplatin 80 mg/m2) | 2 | |
| weekly CDDP (cisplatin 40 mg/m2)*** | 4 | |
| weekly TP (paclitaxel 50 mg/m2, cisplatin 30 mg/m2)*** | 1 | |
ECOG: Eastern Cooperative Oncology Group; CDDP: cisplatin.
*Median ± S.D. (range).
**Mean ± S.D. (range).
***Combined with external pelvic irradiation (1.8 Gy/day).